Targeted Oncology

, Volume 2, Issue 1, pp 7–16 | Cite as

Targeted therapies for renal cell carcinoma

Review
First Online:
Received:
Revised:
Accepted:

Abstract

Renal cell carcinoma (RCC) is the sixth leading cause of cancer-related deaths and is responsible for an estimated 95,000 deaths worldwide. Metastatic RCC is refractory to radiation therapy and traditional chemotherapy. Treatment of metastatic RCC with either interleukin 2 (IL-2) or interferon-alfa (IFN-α) has demonstrated a response rate of approximately 15%. Identification of and research into the von Hippel-Lindau (VHL) gene has led to the development of multi-kinase inhibitors and other novel molecular targeting therapies. Sunitinib and sorafenib are now commercially available agents that can improve progression-free survival. Additional targeting agents are currently under clinical investigation. Combination trials of molecular targeting agents and cytokines are ongoing in the metastatic setting as are trials using molecular targeting agents in the adjuvant setting. This review focuses on the recent advances of targeted therapy for RCC.

Keywords

Targeted therapy Renal cell carcinoma Tyrosine kinase inhibitors Sorafenib Sunitinib Temsirolimus Bevacizumab 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352(9141):1691–1696PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRefGoogle Scholar
  3. 3.
    Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 11(2):171–178PubMedCrossRefGoogle Scholar
  4. 4.
    Linehan WM, Zbar B, Bates SE et al (2001) Cancer of the kidney and ureter, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, PAGoogle Scholar
  5. 5.
    Couillard DR, deVere White RW (1993) Surgery of renal cell carcinoma. Urol Clin North Am 20(2):263–275PubMedGoogle Scholar
  6. 6.
    Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659PubMedCrossRefGoogle Scholar
  7. 7.
    Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970PubMedCrossRefGoogle Scholar
  8. 8.
    Negrier S, Perol D, Ravaud A et al (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (RCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol 23:4511Google Scholar
  9. 9.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696PubMedGoogle Scholar
  10. 10.
    Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127–3132PubMedCrossRefGoogle Scholar
  11. 11.
    McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133–141PubMedCrossRefGoogle Scholar
  12. 12.
    Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20(2):303–321PubMedGoogle Scholar
  13. 13.
    Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2(9):673–682PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163(1):343–347PubMedCrossRefGoogle Scholar
  15. 15.
    Turner KJ, Moore JW, Jones A et al (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62(10):2957–2961PubMedGoogle Scholar
  16. 16.
    Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843–850PubMedGoogle Scholar
  17. 17.
    Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434PubMedCrossRefGoogle Scholar
  18. 18.
    Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL (2004) Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10(8):2584–2586PubMedCrossRefGoogle Scholar
  19. 19.
  20. 20.
    Riedel F, Gotte K, Li M, Hormann K, Grandis JR (2002) EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 21(1):11–16PubMedGoogle Scholar
  21. 21.
    Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7(5):1459–1465PubMedGoogle Scholar
  22. 22.
    Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23(31):7889–7896PubMedCrossRefGoogle Scholar
  23. 23.
    Bukowski RM, Kabbinavar F, Figlin RA et al (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:4523Google Scholar
  24. 24.
    Thompson DS, Greco FA, Spigel DR et al (2006) Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. Proc Am Soc Clin Oncol 24:4594Google Scholar
  25. 25.
    Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337PubMedGoogle Scholar
  26. 26.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471–478PubMedGoogle Scholar
  27. 27.
    Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25–35PubMedCrossRefGoogle Scholar
  28. 28.
    Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24PubMedCrossRefGoogle Scholar
  29. 29.
    Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524PubMedCrossRefGoogle Scholar
  30. 30.
    Motzer RJ, Hutson TE, Tomczak P et al (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (INF-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:LBA3Google Scholar
  31. 31.
    Ronnen EA, Kondagunta GV, Lau C et al (2006) A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:4537Google Scholar
  32. 32.
    De Mulder PH, Roigas S, Gillessen S et al (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 24(18):223SGoogle Scholar
  33. 33.
    Sunitinib malate alone and in combination with interferon alfa as first-line therapy for metastatic renal cell cancer http://www.clinicaltrials.gov/ct/show/NCT00267748?order=4
  34. 34.
    Rini BI, George DJ, Michaelson MD et al (2006) Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:4522Google Scholar
  35. 35.
    Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109PubMedCrossRefGoogle Scholar
  36. 36.
    Awada A, Hendlisz A, Gil T et al (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92(10):1855–1861PubMedCrossRefGoogle Scholar
  37. 37.
    Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472–5480PubMedCrossRefGoogle Scholar
  38. 38.
    Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688–1694PubMedCrossRefGoogle Scholar
  39. 39.
    Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972PubMedCrossRefGoogle Scholar
  40. 40.
    Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512PubMedCrossRefGoogle Scholar
  41. 41.
    Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:4510Google Scholar
  42. 42.
    Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 3(2):226Google Scholar
  43. 43.
    Eisen T, Bukowski RM, Staehler M et al (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc Am Soc Clin Oncol 24:4524Google Scholar
  44. 44.
    Escudier B, Szczylik C, Demkow T et al (2006) Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (INF) in treatment-naive patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:4501Google Scholar
  45. 45.
    Ryan CW, Goldman BH, Lara PN et al (2006) Sorafenib plus interferon-a2b (INF) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Oncol 24:4525Google Scholar
  46. 46.
    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296PubMedCrossRefGoogle Scholar
  47. 47.
    Gollob J, Richmond T, Jones J et al (2006) Phase II trial of sorafenib plus interferon-alpha 2b (INF-α2b) as first-or second-line therapy in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 24:4538Google Scholar
  48. 48.
    Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918PubMedCrossRefGoogle Scholar
  49. 49.
    Hudes G, Carducci M, Tomczak P et al (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+ IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc Am Soc Clin Oncol 24:LBA4Google Scholar
  50. 50.
    Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463PubMedCrossRefGoogle Scholar
  51. 51.
    Mekhail TM, Abou-Jawede RM, Boumerh G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832–841PubMedCrossRefGoogle Scholar
  52. 52.
    Amato RJ, Misellati A, Khan M et al (2006) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 24:4530Google Scholar
  53. 53.
    Zafar Y, Bendell J, Lager J et al (2006) Prelimary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 24:3097Google Scholar
  54. 54.
    Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24):5474–5483PubMedCrossRefGoogle Scholar
  55. 55.
    Rini BI, Rixe O, Bukowski RM et al (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23:4509Google Scholar
  56. 56.
    Phase 2 study of AG-013736 in patients with refractory metastatic renal cell cancer. http://www.clinicaltrials.gov/ct/show/NCT00282048?order=1
  57. 57.
    Keryx Biopharmaceuticals, Inc. announced positive date of KRX-0401 (perifosine) in patients with advanced renal cell carcinoma (RCC). Kidney Cancer News XVI (6). http://app.e2ma.net/app/view:CampaignPublic/id:160.313886690/rid:7471aff0ead7ca63a77f1c3498cd6dd6
  58. 58.
    Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389–4400PubMedCrossRefGoogle Scholar
  59. 59.
    Drevs J, Medinger M, Mross K et al (2005) Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. Proc Am Soc Clin Oncol 23:3002Google Scholar
  60. 60.
    AZD2171 in treating patients with refractory kidney cancer. http://www.clinicaltrials.gov/ct/show/NCT00303862?order=11
  61. 61.
    Suttle B, Hurwitz H, Dowlati A et al (2005) Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc Am Soc Clin Oncol 22:3054Google Scholar
  62. 62.
    Hurwitz H, Dowlati A, Savage S et al (2005) Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Proc Am Soc Clin Oncol 24:3012Google Scholar
  63. 63.
    GW786034 in subjects with locally recurrent or metastatic clear cell renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00244764?order=1
  64. 64.
    GW786034 (pazopanib) in metastatic renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00334282?order=1
  65. 65.
    George D, Michaelson M, Oh W et al (2003) Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:1548Google Scholar
  66. 66.
    Vatalanib and everolimus in treating patients with advanced solid tumors. http://www.clinicaltrials.gov/ct/show/NCT00303732?order=12
  67. 67.
    Eder J, Appleman L, Heath E et al (2006) A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). Proc Am Soc Clin Oncol 24:3041Google Scholar
  68. 68.
    Phase 2 study of XL880 in subjects with papillary renal cell carcinoma. http://www.clinicaltrials.gov/ct/show/NCT00345423?order=3
  69. 69.
    Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery http://www.clinicaltrials.gov/ct/show/NCT00326898?order=1
  70. 70.
    A phase III randomised controlled study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse. http://www.ctu.mrc.ac.uk/studies/RE05.asp
  71. 71.
    Veronese ML, Mosenkis A, Flaherty KT et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24(9):1363–1369PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Internal Medicine, Section of Oncology/Hematology987680 Nebraska Medical CenterOmahaUSA

Personalised recommendations